Diabetic renal disease: From recent studies to improved clinical practice

Diabetic Medicine

Volumn 21, Issue 1, 2004, Pages 4-17

  Mogensen, C E ^a   Cooper, M E ^b,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FOSINOPRIL; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HYPERTENSION; HYPOKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; META ANALYSIS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PROTEIN INTAKE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SALT INTAKE; SIDE EFFECT; SODIUM INTAKE; TREATMENT OUTCOME;

ALBUMINURIA; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 0842265550     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01121.x     Document Type: Review

References (139)

1. Cooper ME. Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219.
2. Lee HB, Ha HJ, Kim SI, Ziyadeh FN. Diabetic kidney disease research: where do we stand at the turn of the century? Kidney Int 2000; 58: S1-S2.
3. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
5. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. N Engl J Med 2000; 342: 145-153.
6. Opie LH. Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension. Lancet 2001; 358: 1829-1831.
7. Hansen HP, Tauber-Lassen E, Jensen BR, Parving H-H. Effect of protein restriction on prognosis in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2002; 62: 220-228.
8. Weir MR, Dworkin LD. Antihypertensive drugs, dietary salt, and renal protection - how low should you go and with which therapy. Am J Kidney Dis 1998; 32: 1-22 [Review].
9. Jandeleit-Dahm K, Cao ZM, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int 1999; 56: S31-S36.
10. Brenner BM. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 2002; 110: 1753-1758.
11. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617-1620.
12. Hommel E, Parving HH, Mathiesen E, Edsberg B, Damkjaer Nielsen M, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed) 1986; 293: 467-470.
13. Marre M, Chatelier G, Leblanc H, Guyenne T-T, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988; 297: 1092-1095.
14. Tatti P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo G et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomised Trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. Diabetes Care 1998; 21: 597-603.
15. Gerstein HC, Yusuf S, Mann JFE, Hoogwerf B, Zinman B, Held C et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
16. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
18. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 1999; 34: 809-817.
19. The ACE Inhibitors in Diabetic nephropathy Trialist group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134: 370-379.
20. Rudberg S, Osterby R, Bangstad HJ, Dahlquist G, Persson B. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus. Diabetologia 1999; 42: 589-595.
21. Osterby R, Bangstad HJ, Nyberg G, Rudberg S. On glomerular structural alterations in type-1 diabetes - companions of early diabetic glomerulopathy. Virchows Arch - Int J Pathol 2001; 438: 129-135.
22. Osterby R, Bangstad HJ, Rudberg S. Follow-up study of glomerular dimensions and cortical interstitium in microalbuminuric type 1 diabetic patients with or without antihypertensive treatment. Nephrol Dialysis Transplantation 2000; 15: 1609-1616.
23. Mathiesen ER, Hommel E, Hansen HP, Smidt UH, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319: 24-25.
24. The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria. Diabetes 2001; 50: 843-850.
25. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
26. Chaturvedi N, Sjolie A-K, StephensonJM, Abrahamian H, Kelpes M, Castellarin A et al. Effect of lisinopril on progression of retinopathy in people with type 1 diabetes. Lancet 1998; 351: 28-31.
27. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36: 1099-1104.
28. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. QJM 2001; 94: 89-94.
29. Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo-to microalbuminuria. A longitudinal study in IDDM patients. Diabetes 1994; 43: 1248-1253.
30. Cooper ME, Johnston CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000; 283: 3177-3179.
31. Jandeleit-Dahm K, Cooper ME. Hypertension and diabetes. Curr Opin Nephrol Hypertens 2002; 11: 221-228.
32. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286-289.
33. Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17: 420-424.
34. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-1581.
35. Agardh CD, Garcia Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-192.
36. Chan JCN, Ko GTC, Leung DHY, Cheung RCK, Cheung MYF, So WY et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
37. Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 1042-1049.
38. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097.
39. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23: B54-B64.
40. Fernandez R, Puig JG, Rodriguez-Perez JC, Garrido J, Redon J. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-856.
41. Mogensen C, Viberti GC, Halimi S, Ritz E, Ruilope L, Jermendy G et al. Treatment based on a low dose combination of perindopril and indapamide reduces albuminuria more effectively than enalapril in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: (Suppl. 1): A21-A22 (Abstract).
42. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and Lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440-1444.
43. Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002; 25: 663-671.
44. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
45. Ravid M, Brosh D, Levi Z, Bardayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus - a randomized, controlled trial. Ann Intern Med 1998; 128: 982-988.
46. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996; 50: 657-664.
47. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998; 53: 1002-1006.
48. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133 [Review].
49. Mogensen CE. Genetics and diabetic renal disease: still a big black hole. Diabetes Care 2003; 26: 1631-1632.
50. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762-769.
51. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes 1997; 46: 1612-1618.
52. Rippin J, Bain SC, Barnett AH. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications 2002; 16: 195-200.
53. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
54. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
55. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
56. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
57. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care 2002; 25: 1909-1913.
58. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
59. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
60. Mifsud SA, Skinner SL, Cooper ME, Kelly DJ, Wilkinson-Berka JL. Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. J Am Soc Nephrol 2002; 13: 684-692.
61. O'Hare JP, Bilous R, Mitchell T, O'Callaghan CJ, Viberti GC, Willoughby R et al. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension results of a randomized controlled trial - results of a randomized controlled trial. Diabetes Care 2000; 23: 1823-1829.
62. Rossing K, Christensen PK, Jensen BR, Parving H-H. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double blind crossover study. Diabetes Care 2002; 25: 95-100.
63. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002; 17: 1019-1024.
64. Azizi M, Chatellier G, Guyene TT, Murietageoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-834.
65. Andersen NH, Mogensen CE. Inhibition of the renin-angiotensin system with particular reference to dual blockade treatment. JRAAS 2001; 2: 146-152.
66. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002; 89: 18A-25A.
67. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
68. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I. Aldosterone in renal disease. Curr Opin Nephrol Hypertension 2001; 10: 105-110 [Review].
69. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37: 677-688.
70. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000; 57: 1408-1411.
71. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926.
72. Epstein M, Buckalew V Jr, Martinez F, Altamirano J, Roniker B, Kleiman J et al. Antiproteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002; 15: 24A.
73. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000; 23: 1725-1730.
74. Mimran A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouse J. Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertens 1988; 6: 919-923.
75. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001; 37: 890-899.
76. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21: 104-110.
77. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000; 23: 888-892.
78. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. Br Med J 1992; 305: 981-985.
79. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84s-92s.
80. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of anti-hypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
81. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29: 744-750.
82. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641-1650.
83. Christensen PK, Akram K, Konig KB, Parving HH. Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. Diabetes Care 2003; 26: 156-162.
84. Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: Potential role of nephrin. J Hypertens 2002; 21: 209-216.
85. Cooper ME, Mundel P, Boner G. Role of nephtin in renal disease including diabetic nephropathy. Semin Nephrol 2002; 22: 393-398.
86. Bakris GL, Weir MR, Shahinfar S, Zhang Z, Douglas J, van Dijk DJ et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-1565.
87. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661.
88. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes - UKPDS 39. Br Med J 1998; 317: 713-720.
89. Schnack C, Hoffmann W, Hopmeier P, Schernthaner G. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1611-1616.
90. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182-1188.
91. Elving LD, Wetzels JF, van Lier HJ, de Nobel E, Berden JH. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. Diabetologia 1994; 37: 604-609.
92. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-1975.
93. Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized crossover study. Nephron 1998; 80: 175-182.
94. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-516.
95. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-1456 [Review].
96. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.
97. Lane PH, Steffes MW, Mauer SM. Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes 1992; 41: 581-586.
98. Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994; 43: 649-655.
99. Sackmann H, Tran-Van T, Tack I, Hanaire-Broutin H, Tauber JP, Ader JL. Contrasting renal functional reserve in very long-term Type I diabetic patients with and without nephropathy. Diabetologia 2000; 43: 227-230.
100. Mogensen CE. Glomerular filtration rate and renal plasma flow in long-term juvenile diabetics without proteinuria. Br Med J 1972; 4: 257-259.
101. Hansen KW, Poulsen PL, Mogensen CE. Ambulatory blood pressure and abnormal albuminuria in type 1 diabetic patients. Kidney Int Suppl 1994; 45: S134-140.
102. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347: 797-805.
103. Poulsen PL, Hansen KW, Mogensen CE. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 260-264 [Letter].
104. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38: E28-32.
105. Hansen KW, Poulsen PL, Ebbehoj E, Mogensen CE. What is hypertension in diabetes? Ambulatory blood pressure in 137 normotensive and normoalbuminuric Type 1 diabetic patients. Diabet Med 2001; 18: 370-373.
106. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF et al. British Hypertension Society guidelines for hypertension management 1999: summary. Br Med J 1999; 319: 630-635.
107. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2445.
108. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
109. Bakris GL, Weir MR, Dequattro V, McMahon FG. Effects of an ACE inhibitor calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-1289.
110. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert R. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomised rats. Kidney Int 2001; 60: 715-721.
111. Davis BJ, Burns WC, Kubota E, Burrell LM, Johnston CI, Cooper ME et al. Renoprotective effects of dual ACE/NEP inhibition in an experimental model of diabetic nephropathy. Diabetologia 2003; 46: 961-971.
112. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
113. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Progression of diabetic nephropathy. Kidney Int 2001; 59: 702-709.
114. Tarnow L, Kjeld T, Knudsen E, Major-Pedersen A, Parving HH. Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in Type I diabetic patients. Diabetologia 2000; 43: 794-799.
115. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002; 25: S85-S89.
116. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.
117. Yu HCM, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998; 98: 2621-2628.
118. Allen TJ, Waldron MJ, Casley D, Jerums G, Cooper ME. Salt restriction reduces hyperfiltration, renal enlargement and albuminuria in experimental diabetes. Diabetes 1997; 46: 119-124.
119. Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG, et al. Sodium restriction and blood pressure in hypertensive type II diabetes: randomized blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. Br Med J 1989; 298: 227-230.
120. Missouris CG, Macgregor GA. Rebound sodium and water retention occurs when diuretic treatment is stopped. Br Med J 1998; 316: 628.
121. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 78-84.
122. Walker JD, Bending JJ, Dodds RA, Mattock MB, Murrells TJ, Keen H et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; 2: 1411-1415.
123. Hermansen K. Diet, blood pressure and hypertension. Br J Nutritrion 2000; 83: S113-S119.
124. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
125. Valmadrid CT, Klein R, Moss SE, Klein BEK. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-1100.
126. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226.
127. Parving HH, Nielsen FS, Bang LE, Smidt UM, Svendsen TL, Chen JW et al. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. Diabetologia 1996; 39: 1590-1597.
128. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
129. Mather HM, Chaturvedi N, Kehely AM. Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with Type 2 diabetes mellitus. Diabet Med 1998; 15: 672-677.
130. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
131. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001; 44: 108-114.
132. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-731.
133. Gilbert RE, Tsalamandris C, Allen TJ, Colville D, Jerums G. Early nephropathy predicts vision-threatening retinal disease in patients with type I diabetes mellitus. J Am Soc Nephrol 1998; 9: 85-89.
134. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
135. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997.
136. Passa P, Chatellier G. TheDiab-HYCAR study. Diabetologia 1996; 39: 1662-1667.
137. Chalmers J, Cooper M, Ferrannini E, Glasziou P, Grobbee D, Hamet P et al. Study rationale and design of ADVANCE: Action in and vascular disease - preterax and diamicron MR evaluation. Diabetologia 2001; 44: 1118-1120.
138. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424.
139. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.